387 related articles for article (PubMed ID: 20501846)
1. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.
Mouchawar J; Korch C; Byers T; Pitts TM; Li E; McCredie MR; Giles GG; Hopper JL; Southey MC
Cancer Res; 2010 Jun; 70(12):4795-800. PubMed ID: 20501846
[TBL] [Abstract][Full Text] [Related]
2. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
3. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of germline TP53 mutations in HER2+ breast cancer patients.
Rath MG; Masciari S; Gelman R; Miron A; Miron P; Foley K; Richardson AL; Krop IE; Verselis SJ; Dillon DA; Garber JE
Breast Cancer Res Treat; 2013 May; 139(1):193-8. PubMed ID: 23580068
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
6. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
7.
da Silva PFF; Goveia RM; Teixeira TB; Gamba BF; de Lima AP; Rogatto SR; Silveira-Lacerda EP
Biomolecules; 2022 Apr; 12(5):. PubMed ID: 35625568
[No Abstract] [Full Text] [Related]
8. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
[TBL] [Abstract][Full Text] [Related]
9. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
11. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
12. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
13. Next generation sequencing is informing phenotype: a TP53 example.
O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
[TBL] [Abstract][Full Text] [Related]
14. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
16. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
17. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Kamihara J; Rana HQ; Garber JE
Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
[TBL] [Abstract][Full Text] [Related]
18. Contribution of de novo and mosaic
Renaux-Petel M; Charbonnier F; Théry JC; Fermey P; Lienard G; Bou J; Coutant S; Vezain M; Kasper E; Fourneaux S; Manase S; Blanluet M; Leheup B; Mansuy L; Champigneulle J; Chappé C; Longy M; Sévenet N; Paillerets BB; Guerrini-Rousseau L; Brugières L; Caron O; Sabourin JC; Tournier I; Baert-Desurmont S; Frébourg T; Bougeard G
J Med Genet; 2018 Mar; 55(3):173-180. PubMed ID: 29070607
[TBL] [Abstract][Full Text] [Related]
19. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
[TBL] [Abstract][Full Text] [Related]
20. Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile.
Franceschi S; Spugnesi L; Aretini P; Lessi F; Scarpitta R; Galli A; Congregati C; Caligo MA; Mazzanti CM
Carcinogenesis; 2017 Sep; 38(9):938-943. PubMed ID: 28911001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]